tbuckley/cabot-search huggingface dataset:
SAT0085 Burden of Rheumatoid Arthritis in Emerging and Developed Countries: Table 1
Authors: R. Moots, V. Strand, M. DiBonaventura, R. Vasilescu, E. Mahgoub, B. Tang
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Whilst studies addressing the burden of rheumatoid arthritis (RA) in both developed and developing countries have been published, there is limited information available comparing these environments. <h3>Objectives</h3> To evaluate and compare the burden of RA in developed and emerging countries. <h3>Methods</h3> Data were analysed from the 2011 and 2012 National Health and Wellness Survey an annual cross-sectional survey conducted in 5 European Union countries (5EU: France, Germany, Italy, Spain, and UK), Japan, US, Brazil, urban China, and urban Russia. Stratified random sampling based on sex and age was used to ensure appropriate representation of the total regional adult populations. Respondents who self-reported a diagnosis of RA were compared to those without on health status (using the SF-12v2 summary scores), work impairment (using the WPAI-GH), and healthcare resource use events in the past six months using generalized linear models, controlling for demographics and health history (e.g., the Charlson comorbidity index [CCI]). <h3>Results</h3> Prevalence of RA was comparable across 5EU, Russia, and USA (0.7% to 1.5%) and slightly lower in Brazil (0.6%). However, prevalence in urban China was highest at 2.80% and lowest in Japan at 0.10% (p&lt;.001). RA patients in emerging countries were younger by approximately 5-10 years than those in developed countries and more likely to be employed (all p&lt;.001). Patients in Russia and China were the most educated of all countries (p&lt;.001), with relatively higher incomes in Brazil and China. US patients had the highest prevalence of obesity (42.4%) and, along with Russia, the greatest comorbidity burden (using the CCI; p&lt;.001). For both developed and emerging countries, RA patients were older with a greater comorbidity burden (p&lt;.001). Contrary to developed countries, RA patients in emerging countries had less of a gender imbalance (47.9% were male) and were more socioeconomically advantaged relative to those without RA. Across developed and emerging countries, patients with RA reported significantly worse health status, and significantly more work impairment and healthcare resource use (all p&lt;.001; Table 1). <h3>Conclusions</h3> A significant and clinically relevant health status, work impairment, and healthcare resource use burden of RA was observed across both developed and emerging countriesBased on patient characteristics of who reports a diagnosis of RA, the results suggest a disproportionate effect of healthcare access in emerging countries. <h3>Disclosure of Interest</h3> R. Moots: None declared, V. Strand Consultant for: Pfizer, Amgen, M. DiBonaventura Employee of: Kantar Health and a paid contractor to Pfizer Inc, R. Vasilescu Employee of: Pfizer Inc, E. Mahgoub Employee of: Pfizer Inc, B. Tang Employee of: Pfizer Inc <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4241
Abstract P6-15-05: A Cyclin-Dependent Kinase Inhibitor P276 Inhibits Growth of Breast Cancer Cell Lines Including Basal-Type/Triple-Negative Alone and in Combination with Chemotherapeutic Drugs
Authors: S Sharma, M Rathos, S Manohar, K Joshi, A Badhwar, F Kharas, V Sonawane, U Chaudhuri, K. Joshi
Journal: Cancer Research (2010)

Abstract Background: Development of novel agents and drug combinations are urgently needed for the treatment of breast cancer especially triple negative breast cancer (TNBC). P276 is a potent cyclin-dependent kinase inhibitor with excellent antiproliferative activity against various human cancer cell lines. Here, we report the activity of P276, as a single agent and in combination with paclitaxel or gemcitabine/carboplatin in TNBC cell lines. Material and Methods: In vitro effect of P276 on breast cancer cell lines was determined by cytotoxicity assay, flow cytometry, western blotting and immunofluorescence studies. The antiangiogenic potential of P276 was evaluated using HIF-1 a and VEGF inhibition assay, wound healing and tube formation. In vivo efficacy was studied using human xenograft models in SCID and nude mice. Results: Human breast cancer cell lines including TNBC, treated with P276 were found to be highly susceptible with IC50 ranging from 0.3 to 1.0 mM. In MCF-7 (Her2-, BRCA+/−) and MDA-MB-231 (ER-, PR-, Her2-). P276 significantly down regulated cell cycle proteins pRbser780, cyclin D1, Cdk4 and antiapoptotic protein Bcl-2 followed by 80-85% apoptosis. P276 treatment also lead to the inhibition of PARP enzyme activity or PARP cleavage depending on the cell type. Interestingly, P276 inhibited the key angiogenic mediators HIF-1 a and VEGF with IC50 of 0.095mM and 0.31mM respectively in reporter gene based assays. These antiangiogenic effects were confirmed by immunofluorescence and migration studies in TNBC cell lines and endothelial tube formation. In breast cancer patient derived tumor cell line MAXF 401 (basal like) xenografts in nude mice, cyclical dosing of P276 showed growth inhibition of 71%. Moreover, combination studies of P276 with paclitaxel or gemcitabine plus carboplatin showed synergistic effect in TNBC cell lines. Discussion: Our studies provide compelling evidence for the clinical development of P276 for the treatment of triple negative breast cancer either as monotherapy or in combination with paclitaxel or gemcitabine/carboplatin. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-15-05.
SARCOPLASMIC RETICULUM CALCIUM UPTAKE CHANGES AND CELL SURVIVAL AFTER EXPERIMENTAL ACUTE MYOCARDIAL INFARCTION
Authors: Dennis Cokkinos, Demetrios Arvanitis, lordanis Mourouzis, Costas Pantos, Evangelia G. Kranias, Despina Sanoudou
Journal: Journal of the American College of Cardiology (2012)
P677 HEPATIC STEATOSIS DOES NOT PREDICT REGRESSION OF LIVER CIRRHOSIS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)
Authors: M. Buti, M.K. Washington, E. Gane, R. Aguilar Schall, J.D. Bornstein, M. Subramanian, J.G. McHutchison, R. Flisiak, H.L.A. Janssen, P. Marcellin
Journal: Journal of Hepatology (2014)
p53 in the Diagnosis of Human Neoplasia
Authors: Jeffrey Cossman, Richard Schlegel
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article p53 in the Diagnosis of Human Neoplasia Get access Jeffrey Cossman, Jeffrey Cossman Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard Schlegel Richard Schlegel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 14, 17 July 1991, Pages 980–981, https://doi.org/10.1093/jnci/83.14.980 Published: 17 July 1991 Article history Received: 10 June 1991 Accepted: 11 June 1991 Published: 17 July 1991
Chronic Autoimmune Thyroiditis
Authors: Colin M. Dayan, Gilbert H. Daniels
Journal: New England Journal of Medicine (1996)

In 1912, Hashimoto described four women in whom the thyroid gland was enlarged and appeared to have been transformed into lymphoid tissue (“struma lymphomatosa”).1 Although the patients were not initially hypothyroid, they became so after thyroid surgery. Over 40 years later, the presence of antithyroid antibodies was reported in patients with this disorder.2 Hashimoto's disease, or Hashimoto's thyroiditis, is now recognized as a form of chronic autoimmune thyroiditis.There is no internationally accepted classification of autoimmune thyroid diseases.3 Some investigators consider autoimmune thyroiditis a histologic diagnosis that can be subdivided into lymphocytic thyroiditis, if only lymphocytic infiltration is present, and . . .
Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis
Authors: R. Hull, J. Hirsh, R. Jay, C. Carter, C. England, M. Gent, A. G. G Turpie, D. McLoughlin, P. Dodd, M. Thomas, G. Raskob, P. Ockelford
Journal: New England Journal of Medicine (1982)

We have previously reported that long-term therapy with warfarin is effective for preventing recurrent venous thromboembolism in patients with proximal-vein thrombosis but that there is an appreciable risk of hemorrhage. To determine whether that risk could be reduced without a loss of effectiveness, we randomly allocated 96 patients with proximal-vein thrombosis to a group receiving less intense anticoagulant therapy, with a mean prothrombin time of 26.9 seconds using the Manchester comparative reagent (corresponding Simplastin time, 15 seconds), or a group given more intense therapy, with a mean Simplastin time of 19.4 seconds (corresponding prothrombin time 41 seconds with the Manchester comparative reagent) (P<0.001). Two of 47 patients (4 per cent) in the less intensely treated group had hemorrhagic complications, as compared with 11 of 49 patients (22 per cent) in the more intensely anticoagulated group (P = 0.015 by the two-tailed test). This difference was due to minor bleeding episodes. The frequency of recurrent venous thromboembolism was low in both groups (2 per cent). Our findings indicate that less intense anticoagulant therapy is associated with a low frequency of recurrent venous thromboembolism (2 per cent) and a reduced risk of hemorrhage. (N Engl J Med. 1982; 307:1676–81.)
Abstract 5215: CXCR6-mediated cellular and molecular events involved in breast cancer cell migration and invasion
Authors: Ashley Triplet, Praveen K. Sharma, Rajesh Singh, James W. Lillard, William E. Grizle, Shailesh Singh
Journal: Cancer Research (2010)

Abstract Optimizing standard treatment modalities for breast cancer has improved the outlook for women afflicted with it. However, 40% breast cancer patients still die from the disease, primarily due to metastasis, which highlights the need for new therapies and better understanding of the mechanisms involved in disease progression. The reason(s) why breast cancer cells preferentially metastasize to lymph nodes, bone, brain, and lung is not fully understood. In this regard, chemokines and their corresponding receptor interactions in metastasis is an area of intense pre-clinical and clinical research. Analysis of breast cancer tissue micro-array in our lab demonstrated expression of CXCR6 by the breast cancer tissue. In confirmation with the TMA, breast cancer cell lines (MCF-7 and MDA-MB-231) also showed higher expression of CXCR6 in comparison to the normal transformed memory epithelial cell line (MCF-10A). We further investigated the role of CXCR6 in breast cancer cell migration and invasion, which are the key steps used by the cancer cells to achieve metastatic goals. Interestingly, breast cancer cells showed higher migratory and invasive potential towards the chemotactic gradients of CXCL16, which is the only natural ligand of CXCR6. This invasive and migratory potential was significantly inhibited after CXCR6 blockade. Our antibody array data show phosphorylation Src, FAK and ERK1/2 in breast cancer cells following CXCL16 treatment as compared to normal breast cancer cell. To determine the molecular mechanisms by which the CXCR6-CXCL16 axis mediates migration and invasion, inhibitors against Src kinase, FAK and ERK1/2 were used during the migration and invasion assay, which resulted in decreased migration and invasion. This suggests that Src, FAK, and ERK1/2 are required for CXCR6-mediated migration and invasion. Furthermore, an increase in F-actin polymerization was observed after CXCL16 treatment, which was significantly inhibited by the pharmacological inhibitors against Src, FAK, and ERK1/2, suggesting their potential role in CXCR6-mediated cytoskeletal rearrangement during breast cancer cell migration and invasion. Taken together, these results indicate clinical and biological significance of CXCR6-CXCL16 axis in breast cancer and targeting this axis may provide new therapeutic option. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5215.
BODY MASS INDEX AND OUTCOMES WITH APIXABAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ARISTOTLE (APIXABAN FOR REDUCTION IN STROKE AND OTHER THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION) TRIAL
Authors: Roopinder K. Sandhu, Justin Ezekowitz, Ulrika Andersson, John Alexander, Christopher Granger, Sigrun Halvorsen, Michael Hanna, Ziad Hijazi, Petr Jansky, Renato Lopes, Lars Wallentin
Journal: Journal of the American College of Cardiology (2015)
Suppression of Aldosterone by Cyproheptadine in Idiopathic Aldosteronism
Authors: Milton D. Gross, Roger J. Grekin, Thomas C. Gniadek, Jesus Z. Villareal
Journal: New England Journal of Medicine (1981)

To study the role of serotonin in regulating the release of aldosterone, we gave single, oral doses of cyproheptadine, an antiserotoninergic agent, to five normal volunteers with high aldosterone levels secondary to sodium deprivation and to 14 patients with aldosteronism (six with idiopathic aldosteronism due to bilateral adrenal hyperplasia and eight with adrenal adenoma). A diet containing 150 mmol of sodium was given to the patients with spontaneous aldosteronism, and one containng 10 mmol of sodium was given to the normal subjects, for three days before treatment and throughout the study. All subjects received dexamethasone, 2 mg daily. Serum aldosterone was measured with the subject in the recumbent position before cyproheptadine administration and at 30-minute intervals for two hours afterward. Serum aldosterone fell significantly (P<0.025) from the basal level in the patients with idiopathic aldosteronism due to hyperplasia. No fall was observed in the normal subjects or in the patients with adenoma. No changes were seen in renin activity, cortisol, sodium, or potassium, in any group after cyproheptadine. Suppression of aldosterone with cyproheptadine suggests a serotonin-mediated aldosterone-stimulating system. Hyperactivity of this system may be the cause of idiopathic aldosteronism associated with adrenal hyperplasia. (N Engl J Med. 1981; 305:1815.)
Mammographic and Clinical Predictors of Drainage Patterns in Breast Lymphoscintigrams Obtained During Sentinel Node Procedures
Authors: DOMINICK LAMONICA, STEPHEN B. EDGE, THELMA HURD, GARY PROULX, PAUL C. STOMPER
Journal: Clinical Nuclear Medicine (2003)

The authors' purpose was to explore the association between mammographic findings and drainage patterns on lymphoscintigrams obtained during sentinel node procedures for breast carcinoma.From July 1997 to March 2000, 132 patients with breast cancer who were included in a prospective mammography-pathology correlation and staging database were imaged 2 hours after perilesional injection of 1 mCi filtered (0. 22 microm) Tc-99m sulfur colloid (4 ml volume) before sentinel node procedures.Sixty-four percent of the scans showed axillary drainage only, 9% showed axillary and internal mammary drainage, and 4% revealed internal mammary drainage only. Twenty-three percent of scans showed no drainage. Of the patients who showed drainage, 17% showed drainage to the internal mammary basin, and 5% showed this exclusively. Internal mammary drainage was seen in 18% (10 of 57) of lateral, 21% (6 of 29) of medial, and 14% (1 of 7) of subareolar lesions (P = NS). No drainage was seen in 22% of patients with predominantly fatty mammographic parenchymal density (>50%) compared with only 8% of patients with predominantly dense (>50%) parenchyma (P < 0.05). Failure to show drainage was more common in women older than 50 years (P < 0.05). Axillary sentinel nodes were identified surgically in 73% of patients with negative scan findings. There was no significant association between scintigraphic drainage and mammographic soft tissue tumor size and appearance, histologic findings, or axillary node status.Dense mammographic parenchyma and age less than 50 years are associated with identification of lymphatic drainage on lymphoscintigrams performed before sentinel node procedures in 91% to 92% of patients. Internal mammary drainage, present in 18% of lateral and 21% of medial lesions, may direct therapy to include internal mammary lymph nodes.
PTU-097 The Benefits Of Using Faecal Calprotectin As A Monitoring Tool To Assess Inflammatory Bowel Disease And Pre-emptively Upregulate Treatment In Asymptomatic Patients
Authors: K Bundhoo, A Aravinthan, T Price, K Lithgo, M Johnson
Journal: Gut (2014)

<h3>Introduction</h3> Calprotectin is an abundant neutrophil protein that is released during inflammation. The level of faecal calprotectin (FC) is useful in differentiating inflammatory bowel disease (IBD) from non-organic functional bowel disorders. FC may also be useful in monitoring patients with IBD to identify acute flares in disease, long before the patient becomes symptomatic. This allows appropriate treatment to be given in situations where disease activity is objectively measured to be greater than any perceived deterioration in symptoms. <h3>Methods</h3> Faecal calprotectin data was collected over a 2 year period from 110 patients with IBD, who underwent regular out-patient assessment. Results were recorded as normal (&lt;50 µg/g), borderline (50–100 µg/g) and elevated (&gt;100 µg/g). A retrospective analysis of management outcome was made from reviewing patient records on the local clinical correspondence store and the new National IBD-Registry. <h3>Results</h3> 44, 5 and 61 patients had normal, borderline and elevated FC levels, respectively. Three patients with normal FC (6.8%), compared to 29 (47.5%) with elevated FC, required up-regulation of their management for symptom control. FC returned to normal levels in those selected for treatment escalation. In total, 104/110 (94.5%) of patients avoided investigative colonoscopy. Six patients did require colonoscopic assessment, 1 had normal FC, 1 was borderline and 4 had elevated FC. Three of these 6 colonoscopic examinations were performed as part of surveillance and 2 were carried out in FC +ive patient, 1 for planned therapeutic dilatation of a known stricture and the other to confirm the severe and extent of their disease prior to referral for surgical intervention. <h3>Conclusion</h3> FC is a useful monitoring tool in IBD and in identifying those who have developed or are about to suffer an acute flare in their disease. This allows adjustment of treatment without having to subject patients to colonoscopic investigation. A positive result directs the need to upregulate management, whilst a negative one can be reassuring, allowing physician to concentrate on treating functional aspects if the patient is symptomatic. <h3>Disclosure of Interest</h3> None Declared.
Abstract 1561: The white adipose tissue is a rich reservoir of two distinct CD34+ mesenchymal and endothelial progenitor populations with a catalytic role in cancer progression
Authors: Ines Martin-Padura, Patrizia Mancuso, Giuliana Gregato, Paola Marighetti, Angelica Calleri, Chiara Corsini, Visnu Lohsiriwat, Jean-Yves Petit, Francesco Bertolini
Journal: Cancer Research (2011)

Abstract A catalytic role has been proposed in neoplastic angiogenesis and cancer progression for bone marrow-derived circulating endothelial progenitors (CEPs). However, in preclinical and clinical studies the quantitative role of marrow-derived CEPs in cancer vascularization was found to be extremely variable. We have found that the human and murine white adipose tissue (WAT) is a very rich reservoir (containing a mean of 320 times more CD45-CD34+ progenitors/mL than the marrow) of two distinct CD45-CD34+ perivascular cell populations with mesenchymal and endothelial differentiation potential. When compared to marrow-derived CD34+ cells in gene expression array studies, purified WAT-CD34+ cells expressed similar levels of stemness-related genes such as Nanog, Sox2, Lin28 and others, and significantly increased levels of angiogenesis-related genes such as CD144, VEGFR2, ALK1 and others. In vitro the two WAT-CD34+ human populations generated fibroblasts, mature mesenchymal cells and mature endothelial cells and endothelial tubes. In aging mice, the number of WATCD34+ cells significantly declined in some WAT compartments but not in the mammary fat pad. When compared to marrow-derived progenitor cells, WAT-CD34+ cells expressed significantly increased (8 fold) levels of FAP-alpha, a crucial suppressor of anti-tumor immunity (Kraman et al, Science 2010). The co-injection of human WATCD34+ cells from lipofilling procedures significantly increased tumor growth and metastases in orthotopic models of human breast cancer in NSG mice, where human WATCD34+ cells contributed to tumor stroma and vascularization. A novel brain/adipocyte-BDNF/leptin axis has been recently proposed to play a potentially relevant role in cancer progression (Cao et al, Cell 2010). WATCD34+ progenitors express high levels of the receptors involved in this axis and our studies suggest a catalytic role in cancer progression and metastases. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1561. doi:10.1158/1538-7445.AM2011-1561
TRENDS IN REAL-WORLD TREATMENT MODIFICATIONS AMONG HIGH-CARDIOVASCULAR DISEASE RISK PATIENTS WITH HYPERLIPIDEMIA
Authors: Rajeshwari S. Punekar, Kathleen Fox, Akshara Richhariya, Shravanthi Gandra, Mark Cziraky, Carly Paoli, Peter Toth
Journal: Journal of the American College of Cardiology (2016)
Large polypoid lymphoid follicles in the stomach causing anemia
Authors: Kyosuke Tanaka, Yasuhiko Hamada, Shunsuke Tano, Kenichiro Nishikawa, Reiko Yamada, Takumi Aota
Journal: Endoscopy (2014)

A 73-year-old woman with type C hepatitis underwent esophagogastroduodenoscopy because of asymptomatic anemia (hemoglobin concentration 8.6 g/dL). Endoscopy revealed a large pedunculated polyp in the greater curvature of the gastric body ([Fig. 1 a]). The polyp was covered for the most part by normal reddish mucosa and partly by an ulcer ([Fig. 1 b]). Biopsy specimens obtained from the polyp and the ulcer showed histopathologically benign tissue. Laboratory tests (serum antibody, fecal antigen, and urea breath test) were negative for Helicobacter pylori. The ulcer healed after administration of a proton pump inhibitor ([Fig. 2 a]), and the anemia improved after administration of iron (hemoglobin concentration 13.5 g/dL). Endoscopic ultrasound showed multiple hypoechoic nodules in the polyp ([Fig. 2 b]). Abdominal computed tomography showed a polyp suspended from the gastric wall ([Fig. 3]).